subject: Diabetes Market Forecast to 2015 [print this page] Diabetes Market Forecast to 2015 Diabetes Market Forecast to 2015
Comprehensive Diabetes Forecast
Diabetes Market Forecast to 2015 provides teams with an in-depth analysis of the global diabetes market. Analysts place critical drug information in a relevant industrywide context. Our study details marketed brands, pipeline products, clinical development, whole drug classes and top drug manufacturers - all in one, easy-to-read format.
To complement the brand and company-specific data, CEI's analysts conducted original research with physicians and drug development/marketing executives.
Give your brand team all the diabetes data it needs to make critical product decisions!
Diabetes Portfolio Profiles
Amylin
Bristol-Myers Squibb
Boehringer Ingelheim
Eli Lilly
GlaxoSmithKline
Merck
Novo Nordisk
Roche
Sanofi-Aventis
Takeda
Products Profiled in Report
Traditional Insulins
Humulin
Novolin
Short-Acting Insulin Analogs
Afresa
Apidra
Humalog
Novolog
VIAject
Novel Insulins
IN-105
Oral-lyn
NN1250/SIBA
NN5401/SIAC
DPP-4 Inhibitors
Alogliptin
Dutogliptin
Galvus (includes Eucreas)
Januvia (includes Janumet)
Ondero
Onglyza
Meglitinides
Prandin
Sulfonylureas
Amaryl
Other
Ilaris
Otelixuzumab
Prochymal
Qnexa
Symlin
Teplizumab
TT-223
Adjunct Therapies
Avapro
Cozaar
Cymbalta
Lucentis
Lyrica
PF-4523655
Radiprodil/RGH-896
Zyvox
Data Included in the Report
Product Profile Content
Background:
Current status of drug (e.g., in development, awaiting approval, on market)
Clinical results and what they mean for the drug's future
Drug's current and projected competitive strength
Current and projected sales position within its class
Assessment of current and future competition
Analysis combines current sales, market landscape and/or clinical trial info with projections and predicted market events
Sales projection charts through 2015
Materiality charts (drug's percentage of company revenue) for 2009 (or first year on market) and 2015
